Sangui Biotech International Inc. (SGBI) Financials Nov 11, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Sangui Biotech International Inc.
Fiscal year is July-June. All values USD millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 17,977 5,563 14,949 105,487 133,470
Cost of Goods Sold (COGS) incl. D&A 9,878 7,828 4,029 11,557 1,261
COGS excluding D&A 7,949 6,601 3,337 10,692 793
Depreciation & Amortization Expense 1,929 1,227 692 865 468
Depreciation 1,929 1,227 692 865 468
Amortization of Intangibles 0 0 0 0 0
Gross Income 8,099 (2,265) 10,920 93,930 132,209
2010 2011 2012 2013 2014 5-year trend
SG&A Expense 1.05M 1.74M 3.72M 1.34M 1.45M
Research & Development 111,567 313,671 104,413 65,010 543,071
Other SG&A 938,442 1.43M 3.62M 1.27M 906,414
Other Operating Expense 0 0 0 1.04M 0
Unusual Expense 0 0 (27,422) 0 0
EBIT after Unusual Expense 0 0 27,422 0 0
Non Operating Income/Expense 715 148,548 138,577 0 (245,800)
Non-Operating Interest Income 0 0 0 25,419 49
Equity in Affiliates (Pretax) 0 (8,508) 0 0 -
Interest Expense 0 0 225 4,573 8,683
Gross Interest Expense 0 0 225 4,573 8,683
Interest Capitalized 0 0 0 0 0
Pretax Income (1.04M) (1.6M) (3.54M) (2.26M) (1.57M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 - - -
Income Tax - Current Foreign 0 0 - - -
Income Tax - Deferred Domestic 0 0 - - -
Income Tax - Deferred Foreign 0 0 - - -
Income Tax Credits 0 0 - - -
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (1.04M) (1.6M) (3.54M) (2.26M) (1.57M)
Minority Interest Expense (68,308) (77,205) (53,191) (168,191) (142,946)
Net Income (972,887) (1.53M) (3.49M) (2.1M) (1.43M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (972,887) (1.53M) (3.49M) (2.1M) (1.43M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (972,887) (1.53M) (3.49M) (2.1M) (1.43M)
EPS (Basic) (0.01) (0.02) (0.03) (0.02) (0.01)
Basic Shares Outstanding 75.89M 93.92M 116.69M 128.55M 137.03M
EPS (Diluted) (0.01) (0.02) (0.03) (0.02) (0.01)
Diluted Shares Outstanding 75.89M 93.92M 116.69M 128.55M 137.03M
EBITDA (1.04M) (1.74M) (3.71M) (2.28M) (1.32M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Sangui Biotech International Inc.
Fiscal year is July-June. All values USD millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 17,977 5,563 14,949 105,487 133,470
Cost of Goods Sold (COGS) incl. D&A 9,878 7,828 4,029 11,557 1,261
COGS excluding D&A 7,949 6,601 3,337 10,692 793
Depreciation & Amortization Expense 1,929 1,227 692 865 468
Depreciation 1,929 1,227 692 865 468
Amortization of Intangibles 0 0 0 0 0
Gross Income 8,099 (2,265) 10,920 93,930 132,209
2010 2011 2012 2013 2014 5-year trend
SG&A Expense 1.05M 1.74M 3.72M 1.34M 1.45M
Research & Development 111,567 313,671 104,413 65,010 543,071
Other SG&A 938,442 1.43M 3.62M 1.27M 906,414
Other Operating Expense 0 0 0 1.04M 0
Unusual Expense 0 0 (27,422) 0 0
EBIT after Unusual Expense 0 0 27,422 0 0
Non Operating Income/Expense 715 148,548 138,577 0 (245,800)
Non-Operating Interest Income 0 0 0 25,419 49
Equity in Affiliates (Pretax) 0 (8,508) 0 0 -
Interest Expense 0 0 225 4,573 8,683
Gross Interest Expense 0 0 225 4,573 8,683
Interest Capitalized 0 0 0 0 0
Pretax Income (1.04M) (1.6M) (3.54M) (2.26M) (1.57M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 - - -
Income Tax - Current Foreign 0 0 - - -
Income Tax - Deferred Domestic 0 0 - - -
Income Tax - Deferred Foreign 0 0 - - -
Income Tax Credits 0 0 - - -
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (1.04M) (1.6M) (3.54M) (2.26M) (1.57M)
Minority Interest Expense (68,308) (77,205) (53,191) (168,191) (142,946)
Net Income (972,887) (1.53M) (3.49M) (2.1M) (1.43M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (972,887) (1.53M) (3.49M) (2.1M) (1.43M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (972,887) (1.53M) (3.49M) (2.1M) (1.43M)
EPS (Basic) (0.01) (0.02) (0.03) (0.02) (0.01)
Basic Shares Outstanding 75.89M 93.92M 116.69M 128.55M 137.03M
EPS (Diluted) (0.01) (0.02) (0.03) (0.02) (0.01)
Diluted Shares Outstanding 75.89M 93.92M 116.69M 128.55M 137.03M
EBITDA (1.04M) (1.74M) (3.71M) (2.28M) (1.32M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
